Basisstatistiken
| CIK | 1800315 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Damora Therapeutics, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 12, 2026 |
DAMORA THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN GRANT NOTICE FOR STOCK OPTIONS Employee Form Exhibit 10.2 DAMORA THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN GRANT NOTICE FOR STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, Damora Therapeutics, Inc. (the “Company”), hereby grants to Participant named below an option (the “Option”) to purchase any part or all of the number of Common Stock that are covered by this Option at the Exercise Price per share, each specified below |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 DAMORA |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2026 DAMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commissio |
|
| May 1, 2026 |
` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 DAMORA THERA |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 20, 2026 |
Exhibit 16.1 April 17, 2026 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 We have read Item 4.01 of Form 8-K dated April 17, 2026 of Damora Therapeutics, Inc. and are in agreement with the statements contained in the paragraphs under (a) Dismissal of Independent Registered Public Accounting Firm therein. We have no basis to agree or disagree with other statements of th |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2026 DAMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2026 |
Exhibit 10.1 February 25, 2026 Jennifer Jarrett Re: Offer of Employment Dear Jennifer: On behalf of the Board of Directors (the “Board”) of Galecto, Inc. (the “Company”), I am very pleased to offer you a position as President and Chief Executive Officer of the Company (“CEO”) and a member of the Board pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated |
|
| March 23, 2026 |
Exhibit 10.2 March 20, 2026 Garrett Winslow Re: Offer of Continued Employment Dear Garrett: On behalf of Damora Therapeutics Inc. (the “Company”), I am very pleased to offer you continued employment with the Company in the role of General Counsel and Corporate Secretary of the Company on the terms pursuant to this letter agreement (the “Agreement”). Provided you accept this offer as indicated by y |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2026 DAMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2026 |
Exhibit 99.1 Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors - Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance - - Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors - - Peter Harwin named Chairman of the Boar |
|
| March 20, 2026 |
DAMORA THERAPEUTICS, INC. 2025 Equity INCENTIVE PLAN Exhibit 99.3 DAMORA THERAPEUTICS, INC. 2025 Equity INCENTIVE PLAN 1. Purpose. The purpose of this 2025 Equity Incentive Plan (the “Plan”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Com |
|
| March 20, 2026 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Damora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0000 |
|
| March 20, 2026 |
DAMORA THERAPEUTICS, INC. 2026 Equity INCENTIVE PLAN EXHIBIT 99.1 DAMORA THERAPEUTICS, INC. 2026 Equity INCENTIVE PLAN 1. Purpose The purpose of this Damora Therapeutics, Inc. 2026 Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Damora Therapeutics, Inc. and its stockholders by providing stock-based compensation and other perform |
|
| March 20, 2026 |
As filed with the Securities and Exchange Commission on March 20, 2026 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. |
|
| March 20, 2026 |
DAMORA THERAPEUTICS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN EXHIBIT 99.2 DAMORA THERAPEUTICS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose The purpose of this Damora Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated Contributions. The Company’s intention is to have the Plan qualify as an “employee stoc |
|
| March 19, 2026 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following is a summary of the material terms of our capital stock of Damora Therapeutics, Inc. (“we,” “us,” “our,” and the “Company”), as well as other material terms of our amended and restated certificate of incorporation, as amended (the “Certificate of Incorporation”), and amended and restated by-laws, as amended (the “By-laws”), and certain provisi |
|
| March 19, 2026 |
Exhibit 10.11 Separation Agreement Galecto Biotech ApS and Galecto Biotech AB and Galecto, Inc. and Hans Thalsgård Schambye Galecto Biotech ApS CVR no. 34878366 Ole Maaløes Vej 3 2200 Copenhagen (the "Company") and Galecto Biotech AB Ole Måløes Vej 3 2200 Copenhagen and Galecto, Inc. 75 State Street, Suite 100 Boston, MA 02109 and Hans Thalsgård Schambye Rigensgade 9B, st. 1316 Copenhagen (the "CE |
|
| March 19, 2026 |
GALECTO BIOTECH Aps CVR no. 34878366 Exhibit 10.10 GALECTO BIOTECH Aps CVR no. 34878366 Ole Maaløes Vej 3 2200 København N (the "Company") and Hans Thalsgård Schambye Rigensgade 9B, st. 1316 København K (the "CEO") (each a "Party" and collectively referred to as the "Parties") have today entered into this Retention Bonus Agreement (the "Retention Bonus Agreement") relating to the service agreement between the Parties, dated 23 April |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 DAMORA THERA |
|
| March 19, 2026 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership Damora Therapeutics, LLC Delaware 100% PharmAkea, Inc. Delaware 100% Damora Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 19, 2026 |
EXHIBIT 10.17 November 10, 2025 Lori Firmani Dear Lori: As you may know, Galecto, Inc. (the “Company”) recently entered into that certain Agreement and Plan of Merger, effective November 10, 2025, pursuant to which the Company acquired Damora Therapeutics, Inc., a Delaware corporation, in an all-stock transaction (the “Transaction”). In connection with the Transaction, we are pleased to offer you |
|
| March 19, 2026 |
Position Compensation Employee Benefits Exhibit 10.16 September 29, 2020 Lori Firmani Dear Lori, Congratulations! Galecto, Inc. ("Galecto" or the "Company") is very pleased to offer you employment with the following initial terms: Position Your position will be the position of Corporate Controller, initially reporting to the CFO, effective November 9, 2020 (the "Start Date"). Your position currently is based in Boston, MA. This is a ful |
|
| March 19, 2026 |
DAMORA THERAPEUTICS, INC. 2025 Equity INCENTIVE PLAN Exhibit 10.3 DAMORA THERAPEUTICS, INC. 2025 Equity INCENTIVE PLAN 1. Purpose. The purpose of this 2025 Equity Incentive Plan (the “Plan”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Com |
|
| March 19, 2026 |
Exhibit 10.13 December 31, 2025 Becker Hewes Re: Offer of Employment Dear Becker: On behalf of Galecto, Inc. (the “Company”), I am very pleased to offer you a position as Chief Medical Officer of the Company (“CMO”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Company will commence as of January 5 |
|
| March 19, 2026 |
Exhibit 10.15 November 10, 2025 Garrett Winslow Dear Garrett: As you may know, Galecto, Inc. (the “Company”) recently entered into that certain Agreement and Plan of Merger, effective November 10, 2025, pursuant to which the Company acquired Damora Therapeutics, Inc., a Delaware corporation, in an all-stock transaction (the “Transaction”). In connection with the Transaction, we are pleased to offe |
|
| March 10, 2026 |
Exhibit 99.1 Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders - Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 - - On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets ex |
|
| March 10, 2026 |
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. 2. The Corporation’s Amended and Restated Certificate of Incorp |
|
| March 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2026 DAMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission |
|
| February 11, 2026 |
Calculation of Filing Fee Tables S-3 Galecto, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| February 11, 2026 |
14,473,685 Shares Galecto, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 14,473,685 Shares Galecto, Inc. UNDERWRITING AGREEMENT February 10, 2026 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Introductory. Galecto, Inc., a Delaware corporation (the “Com |
|
| February 11, 2026 |
14,473,685 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| February 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 10, 2026 |
EX-10.1 Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. ANTIBODY DISCOVERY AND OPTION AGREEMENT THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is enter |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 10, 2026 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. 2. The amendment set forth in this Certificate of Amendment to the Amended and Restated Certificate |
|
| February 10, 2026 |
Calculation of Filing Fee Tables S-3 Galecto, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| February 10, 2026 |
GALECTO, INC. $150,000,000 COMMON STOCK SALES AGREEMENT EX-1.2 Exhibit 1.2 GALECTO, INC. $150,000,000 COMMON STOCK SALES AGREEMENT February 10, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Galecto, Inc. (the “Company”) confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the ter |
|
| February 10, 2026 |
SUBJECT TO COMPLETION, DATED FEBRUARY 10, 2026 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| February 10, 2026 |
GALECTO, INC. Debt Securities Dated as of , 202 as Trustee EX-4.3 Exhibit 4.3 GALECTO, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 3 |
|
| February 10, 2026 |
As filed with the Securities and Exchange Commission on February 10, 2026. S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 10, 2026. |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 12, 2026 |
January 2026 Company Overview EXHIBIT 99.1 Company Logo Disclaimers The information contained in this presentation has been prepared by Galecto Inc. and its affiliates (“Galecto” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without noti |
|
| January 6, 2026 |
EXHIBIT 10.1 December 31, 2025 Sherwin Sattarzadeh [email protected] Re: Offer of Employment Dear Sherwin: On behalf of Galecto, Inc. (the “Company”), I am very pleased to offer you a position as Chief Operating Officer of the Company (“COO”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Compan |
|
| January 6, 2026 |
GALECTO, INC. WARRANT TO PURCHASE COMMON STOCK EXHIBIT 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 2, 2026 |
FIRST AMENDMENT TO THE GALECTO, INC. 2022 INDUCEMENT PLAN EXHIBIT 99.2 FIRST AMENDMENT TO THE GALECTO, INC. 2022 INDUCEMENT PLAN WHEREAS, Galecto, Inc. (the “Company”) maintains the Galecto, Inc. 2022 Inducement Plan effective as of November 17, 2022 (the “Plan”); WHEREAS, pursuant to Section 16 of the Plan, the Company’s Board of Directors (the “Board”) may amend the Plan at any time; and WHEREAS, pursuant to its authority under Section 16 of the Plan, |
|
| January 2, 2026 |
EXHIBIT 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.00001 par va |
|
| January 2, 2026 |
As filed with the Securities and Exchange Commission on January 2, 2026 As filed with the Securities and Exchange Commission on January 2, 2026 Registration No. |
|
| December 31, 2025 |
Galecto, Inc. 60,513,309 Shares Common Stock Offered by the Selling Stockholders 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-292175 PROSPECTUS Galecto, Inc. 60,513,309 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the “Selling Stockholders”), of up to (i) 265,309 shares (“Merger Common Shares”) of our common stock, par v |
|
| December 31, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| December 16, 2025 |
Calculation of Filing Fee Tables S-3 Galecto, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| December 16, 2025 |
As filed with the Securities and Exchange Commission on December 16, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 16, 2025 Registration No. |
|
| December 16, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| December 16, 2025 |
EX-10.2 Exhibit 10.2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. ANTIBODY DISCOVERY AND OPTION AGREEMENT THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is enter |
|
| December 9, 2025 |
Exhibit 3.3 STATE OF DELAWARE CERTIFICATE OF CORRECTION TO THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK OF GALECTO, INC. GALECTO, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”). DOES HEREBY CERTIFY: 1. The name of the corporation is |
|
| December 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2025 (November 10, 2025) GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdictio |
|
| November 10, 2025 |
EX-99.1 Exhibit 99.1 Galecto Announces Acquisition of Damora Therapeutics Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advan |
|
| November 10, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 10, 2025, by and among Galecto, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering t |
|
| November 10, 2025 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 12, 2025, is entered into by and among Galecto, Inc., a Delaware corporation (“Galecto”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used h |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 10, 2025 |
EX-99.2 Exhibit 99.2 Transaction & Company Overview November 2025 DISCLAIMERS The information contained in this presentation has been prepared by Damora Therapeutics, Inc. and its affiliates (“Damora” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject |
|
| November 10, 2025 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: GALECTO, INC., a Delaware corporation; DAYLIGHT MERGER SUB I, INC., a Delaware corporation; DAYLIGHT MERGER SUB II, LLC, a Delaware limited liability company; and DAMORA THERAPEUTICS, INC., a Delaware corporation Dated as of November 10, 2025 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 3 1.1 The Merger 3 1.2 Effects of |
|
| November 10, 2025 |
EX-3.2 Exhibit 3.2 GALECTO, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of [Goodnight], Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Boa |
|
| November 10, 2025 |
EX-3.1 Exhibit 3.1 GALECTO, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Galecto, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board o |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 20, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 30, 2025 |
` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 19, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote |
|
| March 19, 2025 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.7 Galecto, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| March 19, 2025 |
Exhibit 10.16 English Summary of a lease agreement dated November 11, 2024 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”) • Leased Property: The Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. • Term: The term started December 1, 2024 and will end on November 30, 2029. • Deposit: Galecto mu |
|
| March 19, 2025 |
Retention Agreement between Galecto Biotech ApS and Hans Schambye, dated October 7, 2024. Exhibit 10.9 Retention Agreement GALECTO BIOTECH ApS and Hans Thalsgård Schambye GALECTO BIOTECH ApS CVR no. 34878366 Ole Maaløes Vej 3 2200 København N (the "Company") and Hans Thalsgård Schambye [Address] (the "CEO") (each a "Party" and collectively referred to as the "Parties") have today entered into this Retention Agreement (the "Retention Agreement") relating to the service agreement between |
|
| March 19, 2025 |
Certificate of Amendment to Amended and Restated By-laws of the Registrant. EXHIBIT 3.5 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF GALECTO, INC. This Certificate of Amendment (this “Amendment”) to the Amended and Restated By-laws (the “By-laws”) of Galecto, Inc., a Delaware corporation (the “Company”), is effective as of March 13, 2025 and is made pursuant to Article VI, Section 9(a) of the By-laws. 1. Section 5 of Article I of the By-laws is hereby a |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Statement of Company Policy on Insider Trading and Disclosure. EXHIBIT 19.1 GALECTO, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of Galecto, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Policy”) is |
|
| March 19, 2025 |
License Agreement between Bridge Medicines LLC and Rockefeller University, dated February 3, 2020. Exhibit 10.15 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. BRIDGE MEDICINES LICENSE AGREEMENT This BRIDGE MEDICINES LICENSE AGREEMENT (“Agreement”), dated as of January 31, 2020 (the “Effective Date”), is by and between |
|
| March 19, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par value |
|
| March 19, 2025 |
Retention Compensation Agreement between the Registrant and Garrett Winslow, dated October 7, 2024. Exhibit 10.13 October 7, 2024 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation a |
|
| January 16, 2025 |
GLTO / Galecto, Inc. / Novo Holdings A/S - EX-99.I begin 644 ck0001669811-ex99i.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V%L@," P(#8Q M,B W.3)=("]#;VYT96YT(=-VO0'WVP\@()(*NZ 61F5U7; MBS$U?2;S=":>IQ*H)TO][LWFZO]ZL]?O)TO]]<;Z]7OWZY-G=?GW[N]/ M?OK\?OOD]>;M[G:SW]W=/KG\^-O>.K%W=U^>^7OZR>??%\];\/'^19;O[7 M%VJ5KQK]L^W5ZG[[\,'?K2Z??C@V4\/'SQY4:ST!S^]>?B@T*!\5:Q:E>6J M6JDJ,Q^\TYBO+MO5VP:WNHM%?GNNKAP]^O5BM[[ZZ9N'#[[4UO[Z\ 'O M5H-67W[W?+5ZL+ |
|
| November 7, 2024 |
EX-99.1 2 d836936dex991.htm EX-99.1 CUSIP No. 36322Q107 13G Exhibit 99.1 Page 8 of 9 Pages Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| November 7, 2024 |
GLTO / Galecto, Inc. / Sunstone Life Science Ventures A/S - SC 13G Passive Investment SC 13G 1 d836936dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 36322Q107 (CUSIP Number) DECEMBER 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| November 7, 2024 |
GLTO / Galecto, Inc. / Sunstone Life Science Ventures A/S - SC 13G/A Passive Investment SC 13G/A 1 d836950dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALECTO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 36322Q206 (CUSIP Number) SEPTEMBER 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 15, 2024 |
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler Exhibit 99.1 Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON, October 15, 2024 (GLOBE NEWSWIRE) - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of exp |
|
| October 7, 2024 |
Exhibit 3.1 GALECTO, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Galecto, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the Board of Direc |
|
| October 7, 2024 |
Exhibit 10.1 GALECTO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of October 7, 2024 is made by and among Galecto, Inc., a Delaware corporation (“Buyer”), Bridge Medicines LLC, a Delaware limited liability company (the “Seller”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Buyer. WHEREAS, concurrently with the entry int |
|
| October 7, 2024 |
Asset Purchase Agreement by and between the Registrant and Bridge Medicines LLC. Exhibit 2.1 ASSET PURCHASE AGREEMENT between Galecto, inc. as Buyer, and bridge medicines llc as Seller dated as of October 7, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 2 1.1 Definitions 2 1.2 Table of Definitions 9 Article II PURCHASE AND SALE 10 2.1 Purchase and Sale of Assets 10 2.2 Excluded Assets 11 2.3 Assumed Liabilities 12 2.4 Excluded Liabilities 12 2.5 Share Consideration 12 2.6 |
|
| October 7, 2024 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On October 7, 2024, the Company completed the Closing of the Asset Purchase as further described under Item 1.01 of this Current Report on Form 8-K. The following unaudited pro forma condensed consolidated financial information is based upon the historical financial statements of the Company, adjusted to reflect the Closi |
|
| October 7, 2024 |
TRANSFORMING TREATMENT of cancer and liver disease with first-in-class small molecule agents Exhibit 99. |
|
| October 7, 2024 |
Exhibit 99.2 Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 - Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 5, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. Pursuant to Section 242 of the DGCL, this Certificate of Amendment to the Amended and Restated Certific |
|
| August 29, 2024 |
GLTO / Galecto, Inc. / Otto Erik Passive Investment SC 13G/A 1 glto13Agv3.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. 1) Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) August 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 12, 2024 |
Employment Agreement between Galecto, Inc. and Garrett Winslow, dated April 12, 2021. Exhibit 10.1 April 12, 2021 Garrett Winslow [Address] Dear Garrett, Congratulations! Galecto, Inc. (“Galecto” or the “Company”) is very pleased to offer you employment with the following initial terms: Position Your position will be the position of General Counsel, initially reporting to Hans Schambye, effective April 26, 2021 (the “Start Date”). Your position currently is based in Boston, Massach |
|
| August 12, 2024 |
Retention Compensation Agreement between Galecto, Inc. and Garrett Winslow, dated October 19, 2023. Exhibit 10.2 October 19, 2023 Garrett Winslow [Address] Re: Retention Compensation Dear Garrett: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation a |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 24, 2024 |
GLTO / Galecto, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d811382dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +4 |
|
| June 21, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 8, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| March 8, 2024 |
2020 Equity Incentive Plan, and forms of award agreements thereunder. Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Affiliates up |
|
| March 8, 2024 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 8, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par value |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. |
|
| March 8, 2024 |
Incentive Compensation Recovery Policy. Exhibit 97 Galecto, INC. COMPENSATION RECOVERY POLICY November 16, 2023 Galecto, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance wi |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 6, 2023 |
Retention Compensation Agreement between Galecto, Inc. and Jonathan Freve, dated September 26, 2023. Exhibit 10.2 September 26, 2023 Jonathan Freve [Address Omitted] Re: Retention Compensation Dear Jon: As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensat |
|
| November 6, 2023 |
Bonus Agreement between Galecto Biotech ApS and Hans Schambye, dated September 26, 2023. Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED INFORMATION HAS BEEN REPLACED BY ASTERISKS Bonus Agreement GALECTO BIOTECH ApS and Hans Thalsgård Schambye GALECTO BIOTECH ApS CVR no. 34878366 Ole Maaløes Vej 3 2200 København N (the "Company") and Hans Thalsgård |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 23, 2023 |
Exhibit 99.1 Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Boston, MA, October 23, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the d |
|
| October 3, 2023 |
GLTO / Galecto Inc / Otto Erik - GALECTO13G Passive Investment 13G Template SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. |
|
| October 2, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 26, 2023 |
Galecto Announces Plans to Explore Strategic Alternatives Exhibit 99.1 Galecto Announces Plans to Explore Strategic Alternatives Boston, MA, September 26, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the det |
|
| September 18, 2023 |
EX-99.1 2 ss2502095ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to Schedule 13D, dated September 12, 2023, with respect to the common stock of Galecto, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the unde |
|
| September 18, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment SC 13D/A 1 ss2502095sc13da.htm AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII L |
|
| September 5, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| September 5, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| August 17, 2023 |
EX-99.1 2 ss2400578ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 4 to Schedule 13D, dated August 15, 2023, with respect to the common stock of Galecto, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the und |
|
| August 17, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 15, 2023 |
Exhibit 99.1 Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA, August 15, 2023 - Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments f |
|
| August 2, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| August 2, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| July 17, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| July 17, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. (Exa |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 7, 2023 |
GLTO / Galecto Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 6 |
|
| April 7, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. |
|
| March 9, 2023 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 9, 2023 |
Exhibit 99.2 GALECTO, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2022 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Galecto, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company and its Affiliates to acc |
|
| March 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par va |
|
| March 9, 2023 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-260778 AMENDMENT NO. 2 DATED MARCH 9, 2023 to Prospectus Supplement dated November 4, 2021 (To the Prospectus Dated November 4, 2021) PROSPECTUS SUPPLEMENT Up to $50,000,000 Common Stock This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated November 4, 2021 (the “Prospectus Supplement”). This Am |
|
| January 6, 2023 |
EX-99.1 2 glto-ex991.htm EX-99.1 First-in-class small molecule antifibrotic and anticancer agents January 2023 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements about Galecto, Inc.’s (“Galecto” or the “Company”) strategy, future plans, operations and prospects, including, but not limited to, statements regarding the development of Galecto’s compounds and |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 31, 2022 |
Exhibit 99.1 Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022 • Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trial • Galecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis |
|
| September 30, 2022 |
GLTO / Galecto Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne |
|
| September 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 29, 2022 |
Exhibit 99.1 GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET Boston, MA, September 29, 2022 - Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 28, 2022 |
DEF 14A 1 glto-2022-def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 18, 2022 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-260778 AMENDMENT NO. 1 DATED FEBRUARY 18, 2022 to Prospectus Supplement dated November 4, 2021 (To the Prospectus Dated November 4, 2021) PROSPECTUS SUPPLEMENT Up to $50,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this ?Amendment?) amends our prospectus supplement dated November 4, 2021 (the ?Prospectus Supplement?). Thi |
|
| February 17, 2022 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. Delaware 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| February 17, 2022 |
As filed with the Securities and Exchange Commission on February 17, 2022 As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 17, 2022 |
Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, and 10,000,000 shares of preferred stock, par value $0.00001 per share, all of which shares of preferred stock are undesignated. Common Stock Holders of our common stock are entitled to one vote for each share of common stock held of record for the ele |
|
| February 17, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Galecto, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00001 par |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 c FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC |
|
| February 14, 2022 |
GLTO / Galecto Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2022 |
GLTO / Galecto Inc / HBM Healthcare Investments (Cayman) Ltd. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
GLTO / Galecto Inc / Soleus Private Equity Fund I, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
EXHIBIT A JOINT FILING AGREEMENT Soleus Private Equity GP I, LLC, a Delaware limited liability company, Soleus Private Equity Fund I, L. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: GALECTO, INC. Title of Class of Securities: Common Stock CUSIP Number: 36322Q107 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X |
|
| February 9, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 9, 2022 |
Non-Employee Director Compensation Policy, as amended Exhibit 10.1 Galecto, Inc. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of the purpos |
|
| January 27, 2022 |
Exhibit 99.1 Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial Boston, MA, January 27, 2022 - Galecto, Inc. (NASDAQ: |
|
| January 27, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2022 |
First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2022 Exhibit 99. |
|
| November 10, 2021 |
United States securities and exchange commission logo November 10, 2021 Jonathan Freve Chief Financial Officer Galecto, Inc. |
|
| November 10, 2021 |
GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N CORRESP 1 filename1.htm GALECTO, INC. Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark November 10, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Galecto, Inc.: Registration Statement on Form S-3 filed November 4, 2021 (File No. 333-260778) Ladies and Gentlemen: Pursuant to Rule 461 under the |
|
| November 4, 2021 |
Sales Agreement, dated November 4, 2021, by and between the Registrant and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Galecto, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, pa |
|
| November 4, 2021 |
Exhibit 4.3 GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01Definitions of Terms1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01Designation and Terms of Securities5 Section 2.02Form of Securities and Trustee?s Certificate8 Section 2.03Denom |
|
| November 4, 2021 |
Form of Subordinated Indenture Exhibit 4.4 GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Secti |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| August 5, 2021 |
Exhibit 10.1 English Summary of a lease agreement dated April 15, 2021 (the ?Lease?) by and between Galecto Biotech ApS (?Galecto?) and Symbion A/S (the ?Landlord?) ? Leased Property: The Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. ? Term: The term started at May 1, 2021 and will end on January 31, 2025. ? Deposit: Galecto must prov |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 6, 2021 |
Executive Separation Benefits Plan Exhibit 10.1 Galecto, Inc. Executive Separation Benefits Plan 1. Establishment of Plan. Galecto, Inc., a Delaware corporation, is establishing this unfunded separation benefits plan (the ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA. The Plan is in effect for Covered Employees of the Company and its Applicable Subsidiaries who experience a Covere |
|
| May 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| April 14, 2021 |
DEFA14A 1 glto-defa14a20210414.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39655 GALECTO, INC. |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 29, 2021 |
2020 Equity Incentive Plan, and forms of award agreements thereunder. Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN (1) GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the ?Company?) and its Affiliates upon whos |
|
| March 29, 2021 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction of Organization Percentage Ownership PharmAkea, Inc. California 100% Galecto Securities Corporation Massachusetts 100% Galecto Biotech AB Sweden 100% Galecto Biotech ApS Denmark 100% owned by Galecto Biotech AB |
|
| March 15, 2021 |
Exhibit 99.1 Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB B |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 12, 2021 |
JANUS HENDERSON GROUP PLC OWNS >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: GALECTO, INC. Title of Class of Securities: Common Stock CUSIP Number: 36322Q107 Date of Event Which Requires Filing of this Statement: 12/31/2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galecto, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 8, 2021 |
Galecto Appoints Anne Prener to its Board of Directors Exhibit 99.1 Galecto Appoints Anne Prener to its Board of Directors Boston, Jan. 8, 2021 (GLOBE NEWSWIRE) – Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors. “We warmly welcome Anne to our Board. She will be a tremendous asset with |
|
| January 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2021 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2021 |
First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2021 Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39655 GALECTO, INC. |
|
| November 23, 2020 |
Non-Employee Director Compensation Policy EX-10.1 Exhibit 10.1 GALECTO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy of Galecto, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries. In furtherance of th |
|
| November 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 23, 2020 |
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors EX-99.1 Exhibit 99.1 Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors • Has extensive experience in pharma and biotech in U.S., Europe and globally • Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months Boston, MA/Copenhagen, Denmark, November 23, 2020 - Galecto, Inc. (NASDAQ: GLTO), a clinical stage b |
|
| November 12, 2020 |
GLTO / Galecto, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galecto, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) November 2, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 12, 2020 |
GLTO / Galecto, Inc. / Soleus Private Equity Fund I, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 36322Q107 (CUSIP Number) November 2, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 12, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 12, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bih |
|
| November 6, 2020 |
GLTO / Galecto, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Galecto, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36322Q107 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue |
|
| November 6, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 6, 2020, with respect to the ordinary shares of Galecto, Inc. |
|
| November 5, 2020 |
Form of lock-up from directors, officers or other stockholders October , 2020 EX-99.1 Exhibit 99.1 Form of lock-up from directors, officers or other stockholders October , 2020 BofA Securities, Inc., SVB Leerink LLC, Credit Suisse Securities (USA) LLC as Representatives of the several Underwriters to be named in the within-mentioned Underwriting Agreement c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th |
|
| November 5, 2020 |
GLTO / Galecto, Inc. / Novo Holdings A/S - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GALECTO, INC. (Name of Issuer) Common Stock, par value $ 0.00001 per share (Title of Class of Securities) 36322Q107 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Kennedy, |
|
| November 4, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 001-39655 37-1957007 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2020 |
Amended and Restated By-laws of Galecto, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF GALECTO, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may su |
|
| November 4, 2020 |
S-8 As filed with the Securities and Exchange Commission on November 4, 2020 Registration No. |
|
| November 4, 2020 |
Amended and Restated Certificate of Incorporation of Galecto, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was |
|
| October 30, 2020 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249369 PROSPECTUS 5,666,667 Shares Common Stock This is Galecto, Inc.’s initial public offering. We are selling 5,666,667 shares of our common stock. The initial public offering price is $15.00 per share. Currently, no public market exists for our common stock. Our common stock has been approved for listing on The Nasdaq |
|
| October 28, 2020 |
begin 644 8ACertGLTO.docx.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED'0O26UA9V5"+TEM86=E M0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R+C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT)S-6VU3XS@2DX5T$U=567;(&PWFSY:BI5$&!V M[H;9O8&M^;"S'T(PX",DD!A8?MG^O>UNV8X#UN0V*+F;&OPBR^I'W:U^D[.W M/RWRR\&P8.?[^T7Q6!XG5VP7?.)G>[9T]WV5[/P^N\O&@R"?CO=.'\P*; M?LP&%]FTUV,'AW |
|
| October 26, 2020 |
CORRESP Goodwin Procter LLP 620 8th Avenue New York, NY 10018 goodwinlaw.com +1 212 813 8800 October 26, 2020 VIA EDGAR Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Erez Chimovits, Søren Lemonius, Chandra Leo and Karen Wagner Res |
|
| October 23, 2020 |
Registration Statement on Form 8-A Form 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 GALECTO, INC. (Exact name of registrant as specified in its charter) Delaware 37-1957007 (State of incorporation or organization) (I.R.S. Employer Identification No.) Ole Maalos Vej 3 D |
|
| October 23, 2020 |
CORRESP October 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Registration Statement on Form S-1, as amended (Registration No. 333-249369) Dear Mr. Field: In connection with the above-referenced Registration Statement, as |
|
| October 23, 2020 |
CORRESP VIA EDGAR October 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Donald Field Susan Block Kristin Lochhead Kate Tillan Re: Galecto, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-249369 Requested Date: October 27, 2020 Requested Time: 4:00 p.m. Eastern St |
|
| October 22, 2020 |
Employment Agreement between Galecto, Inc. and Jonathan Freve, dated March 11, 2020. EX-10.12 Exhibit 10.12 Jonathan P. Freve Dear Jon: On behalf of Galecto, Inc. a Delaware corporation (the “Company”), I am pleased to set forth below the terms of your employment with the Company, which will take effect as of April 20, 2020 (or a mutually agreed upon alternative date): 1. You will be employed to serve on a full-time basis as Chief Financial Officer of the Company. As Chief Financi |
|
| October 22, 2020 |
2020 Stock Option and Grant Plan. EX-10.1 Exhibit 10.1 GALECTO, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Galecto, Inc., a Delaware corporation (including any successor enti |
|
| October 22, 2020 |
EX-10.14 Exhibit 10.14 English Summary of a lease agreement dated May 4, 2020 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and COBIS A/S (the “Landlord”) • Leased Property: the Lease is for the purpose of office space, with its address: Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark. • Term: The term started at June 1, 2020 and will end on October 31, 2021 • Deposit: Galecto must |
|
| October 22, 2020 |
Form of Indemnification Agreement between the Registrant and each of its directors. EX-10.5 Exhibit 10.5 GALECTO, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc, a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; W |
|
| October 22, 2020 |
Specimen Common Stock Certificate. EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# Exhibit 4.1 COMMON STOCK PAR VALUE $0.00001 COMMON STOCK Certificate Number ZQ00000000 GALECTO, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Shares THIS CERTIFIES THAT SEE REVERSE FOR CERTAIN DEFINITIONS is the owner of THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT |
|
| October 22, 2020 |
EX-10.2 Exhibit 10.2 GALECTO, INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Galecto, Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Galecto, Inc., a Delaware corporation (including any successor entity, the “Company”) and its Affil |
|
| October 22, 2020 |
Form of Indemnification Agreement between the Registrant and each of its executive officers. EX-10.4 Exhibit 10.4 GALECTO, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; |
|
| October 22, 2020 |
EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. Galecto, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Galecto, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was |
|
| October 22, 2020 |
EX-4.2 Exhibit 4.2 FINAL AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 7 2.3 Underwriting Requirements 7 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 10 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchange Act 12 |
|
| October 22, 2020 |
Senior Executive Cash Incentive Bonus Plan. EX-10.3 Exhibit 10.3 GALECTO, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Galecto, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those o |
|
| October 22, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on October 22, 2020 Registration No. |
|
| October 22, 2020 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GALECTO, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Galecto, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name |
